SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2016 / Cilt: 31 - Sayı: 2

Different Central Localizations, Different Histopathologies, Benefits, and Side Effects of Radiotherapy in Neurocytoma

Ahmet KARADENİZ
Kamuran İBİŞ
Rasim MERAL
Murat GÜVELİ
Selnur ÖZKURT
Bilge BİLGİÇ
Musa ALTUN
Pages
39–44
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RT is suggested only for subtotally resected tumors, recurrent tumors, or tumors with atypical characteristics due to delayed side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE Neurocytoma is a rare tumor of central nervous system (CNS).
📊
Key Findings & Data:METHODS Following a retrospective evaluation of 2186 CNS tumors treated at the university oncology institute, 6 cases of neurocytoma were found.
💡
Conclusion & Impact:RT is suggested only for subtotally resected tumors, recurrent tumors, or tumors with atypical characteristics due to delayed side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE Neurocytoma is a rare tumor of central nervous system (CNS). The present study is an analysis of benefits and risks of radiotherapy (RT) after surgery. METHODS Following a retrospective evaluation of 2186 CNS tumors treated at the university oncology institute, 6 cases of neurocytoma were found. These 6 cases were analyzed according to patient sex, age, location of tumor, treatment type, and survival. RESULTS Median patient age was 40 years. Four tumors were centrally located, and the remaining 2 tumors were located in the extraventricular region. All of the patients received 50–60 Gy of conventional irradiation. Median length of follow-up was 51 months (range: 15–88 months). In this study, 5-year survival rate was 60%. CONCLUSION Primary treatment for neurocytoma is surgery. RT is suggested only for subtotally resected tumors, recurrent tumors, or tumors with atypical characteristics due to delayed side effects.

🔖

Cite This Article

KARADENİZ, A., İBİŞ, K., MERAL, R., GÜVELİ, M., ÖZKURT, S., BİLGİÇ, B., ALTUN, M. (2022). Different Central Localizations, Different Histopathologies, Benefits, and Side Effects of Radiotherapy in Neurocytoma. Türk Onkoloji Dergisi, Cilt: 31 - Sayı: 2, 39–44. https://ajindex.com/articles/639309

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hassoun J, Gambarelli D, Grisoli F, Pellet W, Salamon G, Pellissier JF, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol 1982;56(2):151–6
  2. Bertalanffy A, Roessler K, Dietrich W, Aichholzer M, Prayer D, Ertl A, et al. Gamma knife radiosurgery of recurrent central neurocytomas: a preliminary report. J Neurol Neurosurg Psychiatry 2001;70(4):489–93
  3. Chen CL, Shen CC, Wang J, Lu CH, Lee HT. Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg 2008;110(2):129–36
  4. Choudhari KA, Kaliaperumal C, Jain A, Sarkar C, Soo MY, Rades D, et al. Central neurocytoma: a multi-disciplinary review. Br J Neurosurg 2009;23(6):585–95
  5. Sharma MC, Deb P, Sharma S, Sarkar C. Neurocytoma: a comprehensive review. Neurosurg Rev 2006;29(4):270–85
  6. Matsunaga S, Shuto T, Suenaga J, Inomori S, Fujino H. Gamma knife radiosurgery for central neurocytomas. Neurol Med Chir (Tokyo) 2010;50(2):107–13
  7. Yarsagil MG, von Ammon K, von Deimling A, Valavanis A, Wichmann W, Wiestler OD. Central neurocytoma: histopathological variants and therapeutic approach. J Neurosurg 1992;76:32–7
  8. Rades D, Schild SE, Fehlauer F. Prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology 2004;62(6):987–9
  9. Hassoun J, Söylemezoglu F, Gambarelli D, FigarellaBranger D, von Ammon K, Kleihues P. Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol 1993;3(3):297–306
  10. Shah T, Jayasundar R, Singh VP, Sarkar C. MRS characterization of central neurocytomas using glycine. NMR Biomed 2011;24(10):1408–13. 11.Rades D, Schild SE. Treatment recommendations for the various subgroups of neurocytomas. J Neurooncol 2006;77(3):305–9. 12.Rades D, Fehlauer F, Schild SE. Treatment of atypical neurocytomas. Cancer 2004;100(4):814–7. 13.Ashkan K, Casey AT, D’Arrigo C, Harkness WF, Thomas DG. Benign central neurocytoma. Cancer 2000;89:1111–20. 14.Kapoor N, Gandhi A, Chaurasia AK. Central neurocytoma in the vermis of the cerebellum. Indian J Pathol Microbiol 2009;52(1):108–9
  11. Vasiljevic A, François P, Loundou A, Fèvre-Montange M, Jouvet A, Roche PH, et al. Prognostic factors in central neurocytomas: a multicenter study of 71 cases. Am J Surg Pathol 2012;36(2):220–7
  12. Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, et al. Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys 2007;67(